ImmunityBio, Inc. (IBRX) shares declined 6.65 percent to $7.22, down $0.51 on Friday, despite the company presenting new patient survey findings related to bladder cancer treatment preferences at ISPOR 2026.
The stock is currently trading at $7.22, compared with a previous close of $7.74 on the Nasdaq. It opened at $7.64 and traded between $7.17 and $7.69 during the session, with volume reaching 6.78 million shares, below the average daily volume of 22.81 million shares.
ImmunityBio Inc. released data from a mixed-methods study conducted with Fight Bladder Cancer examining treatment priorities among patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.
The study found that patient preferences varied widely depending on age, prior treatment experience, and quality-of-life considerations. Patients currently receiving BCG treatment generally preferred bladder-preserving approaches, while those who had previously undergone radical cystectomy were more likely to support repeating the procedure.
ImmunityBio shares have traded between $1.95 and $12.43 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.